BridgeBio Pharma's Upcoming Presentation at HFSA Meeting
BridgeBio Pharma, a pioneering company in the field of genetic diseases, is gearing up to share exciting new data at an upcoming scientific meeting. The company, known for its innovative treatments, has announced it will present compelling cardiovascular outcomes from its ATTRibute-CM study at the Heart Failure Society of America's Annual Scientific Meeting.
Overview of Presentations
This presentation will feature an assortment of formats, including one late-breaking clinical trial oral presentation, an additional oral presentation, and three poster sessions. These sessions promise to provide valuable insights into cardiovascular health, especially pertaining to transthyretin amyloidosis cardiomyopathy (ATTR-CM).
Late Breaking Clinical Trials Presentation
One of the highlights of the meeting will be the late-breaking clinical trials presentation titled Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM. This talk will be presented by Dr. Ahmad Masri of Oregon Health & Science University on Sunday morning. This analysis is anticipated to shed light on how Acoramidis impacts both recurrent and cumulative cardiovascular outcomes in patients.
Significant Oral Presentation
Additionally, on Saturday, Dr. Lily Stern from the Cedars-Sinai Heart Institute will deliver an oral presentation highlighting the pivotal findings of a study demonstrating that continuous Acoramidis treatment significantly reduces the risk of all-cause mortality and cardiovascular-related hospitalizations in patients with wild-type and variant TTR amyloidosis cardiomyopathy at 42 months.
Informative Poster Sessions
The poster sessions, scheduled for Saturday and Sunday, will further explore notable aspects of Acoramidis' therapeutic profile. One poster will delve into how Acoramidis mitigates the rise in NT-proBNP levels observed in patients undergoing treatment for variant transthyretin amyloid cardiomyopathy. Another session will discuss the effect of Acoramidis on cardiac conduction abnormalities related to this rare condition.
Investigation of State-Level Incidence
A third poster will examine state-level differences in the incidence of transthyretin amyloid cardiomyopathy in U.S. veterans, a critical topic as the understanding of this disease evolves with the introduction of new therapies.
About Acorabidis
Acorabidis (Attruby™) is a transthyretin stabilizer indicated for treating the cardiomyopathy of both wild-type and variant transthyretin-mediated amyloidosis (ATTR-CM) in adults. This treatment is focused on reducing cardiovascular deaths and hospitalizations related to cardiovascular issues.
Safety Information
While Acorabidis has shown promising results, it's essential to be aware of the safety information regarding its use. Adverse reactions primarily include diarrhea and upper abdominal pain, which were mostly mild and resolve without discontinuation of the medication. Comparative discontinuation rates for both Acorabidis and placebo treatments were similar.
About BridgeBio Pharma
Founded in 2015, BridgeBio Pharma is dedicated to discovering and delivering transformative medicines for patients affected by genetic diseases. The company's mission is to apply genetic medicine advances rapidly to enhance patient care. With a stable pipeline encompassing various stages of development from early science to advanced clinical trials, BridgeBio is poised to make a significant impact in the life sciences arena.
Contact Information
For Media Inquiries:
Bubba Murarka, Executive Vice President, Corporate Development
Email: contact@bridgebio.com
Phone: (650)-789-8220
For Investor Relations:
Chinmay Shukla, Senior Vice President, Strategic Finance
Email: ir@bridgebio.com
Frequently Asked Questions
What is the focus of BridgeBio Pharma?
BridgeBio Pharma specializes in the treatment of genetic diseases through innovative biopharmaceutical solutions.
What will BridgeBio present at the HFSA Annual Meeting?
They will present new cardiovascular outcomes data from the ATTRibute-CM study on treatments for transthyretin amyloidosis cardiomyopathy.
Who are the presenters for the late-breaking clinical trials?
The late-breaking presentation will be led by Dr. Ahmad Masri from Oregon Health & Science University.
What safety information should patients be aware of regarding Acorabidis?
Common adverse reactions include diarrhea and abdominal pain, mostly mild and manageable without treatment cancellation.
When was BridgeBio Pharma founded?
BridgeBio Pharma was established in 2015 and has since been focused on addressing genetic diseases.
